Rhema Vaithianathan

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. ncbi Supply-side cost sharing when patients and doctors collude
    Rhema Vaithianathan
    Department of Economics, University of Auckland, PBN 92019, Auckland, New Zealand
    J Health Econ 22:763-80. 2003
  2. ncbi Health insurance and imperfect competition in the health care market
    Rhema Vaithianathan
    University of Auckland, Department of Economics, PBN 92019, Auckland, New Zealand
    J Health Econ 25:1193-202. 2006
  3. ncbi Better the devil you know than the doctor you don't: is advertising drugs to doctors more harmful than advertising to patients?
    Rhema Vaithianathan
    Department of Economics, University of Auckland, Auckland, New Zealand
    J Health Serv Res Policy 11:235-9. 2006
  4. ncbi Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey
    Rhema Vaithianathan
    Department of Economics, University of Auckland, Auckland, New Zealand
    Drug Saf 32:335-43. 2009
  5. ncbi Building on myths: an economist's response to the Ministerial Review Group Report on the health system
    Rhema Vaithianathan
    Department of Economics, University of Auckland, Auckland, New Zealand
    N Z Med J 123:79-83. 2010
  6. ncbi The NHS as an insurer
    Rhema Vaithianathan
    University of Auckland, Auckland, New Zealand
    J Health Serv Res Policy 15:171-3. 2010

Detail Information

Publications6

  1. ncbi Supply-side cost sharing when patients and doctors collude
    Rhema Vaithianathan
    Department of Economics, University of Auckland, PBN 92019, Auckland, New Zealand
    J Health Econ 22:763-80. 2003
    ..If patients have a high willingness to pay or are informed, then allowing collusion may be preferred...
  2. ncbi Health insurance and imperfect competition in the health care market
    Rhema Vaithianathan
    University of Auckland, Department of Economics, PBN 92019, Auckland, New Zealand
    J Health Econ 25:1193-202. 2006
    ..The results suggest a beneficial role for Government intervention, either in the insurance or the health care market...
  3. ncbi Better the devil you know than the doctor you don't: is advertising drugs to doctors more harmful than advertising to patients?
    Rhema Vaithianathan
    Department of Economics, University of Auckland, Auckland, New Zealand
    J Health Serv Res Policy 11:235-9. 2006
    ..This is particularly apt, given the calls for similar transparency rules to address the potential conflict of interest between drug companies and researchers...
  4. ncbi Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey
    Rhema Vaithianathan
    Department of Economics, University of Auckland, Auckland, New Zealand
    Drug Saf 32:335-43. 2009
    ..Selective cyclo-oxygenase 2 inhibitors ('coxibs') have been demonstrated to increase cardiovascular risk, but the cumulative burden of adverse effects in the US population is uncertain...
  5. ncbi Building on myths: an economist's response to the Ministerial Review Group Report on the health system
    Rhema Vaithianathan
    Department of Economics, University of Auckland, Auckland, New Zealand
    N Z Med J 123:79-83. 2010
    ..Restructuring is an extremely expensive exercise--and should only be done when there is a compelling logic to the new structure...
  6. ncbi The NHS as an insurer
    Rhema Vaithianathan
    University of Auckland, Auckland, New Zealand
    J Health Serv Res Policy 15:171-3. 2010
    ..Insurance value should be a guiding principle for NHS decision-makers...